Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 4:13 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 289–312 of 3,693 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Daily dosing Clear all
Terminated Phase 4 Interventional Results available

Prednisone Withdrawal Versus Prednisone Maintenance After Kidney Transplant

NCT00596947
View directory record Official record
Conditions
Transplants and Implants
Interventions
Prednisone, rabbit antithymocyte globulin, Tacrolimus, Mycophenolate mofetil
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
19 Years to 74 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 15, 2017 · Synced Oct 29, 2026, 4:13 PM EDT
Completed Phase 2 Interventional Results available

Vaccination Response in Tecfidera-Treated Versus Interferon-Treated Participants With Relapsing Forms of Multiple Sclerosis.

NCT02097849
View directory record Official record
Conditions
Relapsing Forms of Multiple Sclerosis
Interventions
dimethyl fumarate, tetanus diphtheria toxoids vaccine, 23-valent pneumococcal polysaccharide vaccine, meningococcal polysaccharide diphtheria conjugate vaccine (quadrivalent), non-pegylated interferon
Drug · Biological
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 55 Years
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
14
States / cities
Gilbert, Arizona • Thornton, Colorado • Fort Lauderdale, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2017 · Synced Oct 29, 2026, 4:13 PM EDT
Completed Phase 3 Interventional Results available

A Study of Subjects Switched to Lurasidone for the Treatment of Schizophrenia or Schizoaffective Disorder

NCT01143090
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Lurasidone HCl
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years and older
Enrollment
149 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
27
States / cities
Little Rock, Arkansas • Escondido, California • Garden Grove, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2015 · Synced Oct 29, 2026, 4:13 PM EDT
Completed Phase 1 Interventional Results available

Study Of Anti-IGF-IR CP-751,871 In Patients With Solid Tumors

NCT00474760
View directory record Official record
Conditions
Sarcoma, Ewing's
Interventions
CP-751,871
Drug
Lead sponsor
Pfizer
Industry
Eligibility
9 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
2
States / cities
Ann Arbor, Michigan • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 17, 2013 · Synced Oct 29, 2026, 4:13 PM EDT
Completed Phase 2 Interventional Results available

Study Evaluating Safety and Efficacy of Ropanicant in MDD Patients

NCT06126497
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Ropanicant
Drug
Lead sponsor
Suven Life Sciences Limited
Industry
Eligibility
18 Years to 65 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
10
States / cities
Bellflower, California • Orange, California • Torrance, California + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Oct 29, 2026, 4:13 PM EDT
Terminated Phase 2 Interventional Results available

A Study of Orally Administered JBPOS0101 in Refractory Infantile Spasms Patients

NCT03976076
View directory record Official record
Conditions
Refractory Infantile Spasms
Interventions
JBPOS0101
Drug
Lead sponsor
Bio-Pharm Solutions Co., Ltd.
Industry
Eligibility
6 Months to 36 Months
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
17
States / cities
Little Rock, Arkansas • Los Angeles, California • San Francisco, California + 13 more
Source: ClinicalTrials.gov public record
Updated Aug 22, 2024 · Synced Oct 29, 2026, 4:13 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Interaction of Buprenorphine With HIV Medications and Tuberculosis Medications

NCT00877591
View directory record Official record
Conditions
Opioid Dependency, HIV Infections
Interventions
Fosamprenavir/Ritonavir, Darunavir/Ritonavir, Rifampin, Rifabutin, Buprenorphine
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2013
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 6, 2014 · Synced Oct 29, 2026, 4:13 PM EDT
Completed Phase 2 Interventional Results available

Doxorubicin With Upfront Dexrazoxane for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma

NCT02584309
View directory record Official record
Conditions
Sarcoma, Soft Tissue, Soft Tissue Sarcoma, Undifferentiated Pleomorphic Sarcoma, Leiomyosarcoma, Liposarcoma, Synovial Sarcoma, Myxofibrosarcoma, Angiosarcoma, Fibrosarcoma, Malignant Peripheral Nerve Sheath Tumor, Epithelioid Sarcoma
Interventions
Dexrazoxane, Doxorubicin
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Nov 7, 2023 · Synced Oct 29, 2026, 4:13 PM EDT
Completed Phase 3 Interventional

Study of Daily Dosing With Levalbuterol, Racemic Albuterol, and Placebo in Pediatric Subjects With Asthma

NCT00073814
View directory record Official record
Conditions
Asthma
Interventions
Levalbuterol tartrate MDI, racemic albuterol MDI, Placebo
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
4 Years to 11 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
45
States / cities
Montgomery, Alabama • Jonesboro, Arkansas • Corona, California + 39 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2012 · Synced Oct 29, 2026, 4:13 PM EDT
Recruiting Phase 4 Interventional

Precision Pain Management - A Randomized Clinical Trial Assessing the Efficacy of Suzetrigine on Postoperative Analgesia Among Surgical Patients at Higher Risk for Persistent Postoperative Opioid Use (POU)

NCT07672015
View directory record Official record
Conditions
Opioid Consumption, Postoperative
Interventions
Suzetrigine, Standard Care (in control arm)
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Oct 29, 2026, 4:13 PM EDT
Completed Phase 1 Interventional

Optimal Fecal Microbiota Transplant Dosing for Mild to Moderate Ulcerative Colitis

NCT03006809
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Fecal Microbiota Transplantation (FMT), OpenBiome, pretreatment antibiotics
Biological · Other
Lead sponsor
Najwa Elnachef
Other
Eligibility
18 Years to 64 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 28, 2021 · Synced Oct 29, 2026, 4:13 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

A Study to Train a Machine Learning Algorithm for an Evaluation of the Use of Biometric Data Captured at the Wrist for the Identification of Acute Opioid Use Events and the Quantification of Opioid Withdrawal in Opioid Dependent Individuals

NCT07405398
View directory record Official record
Conditions
Treatment for Opioid Use Disorder
Interventions
Train and evaluate the accuracy and reliability of the Strength Band Platform in identifying acute opioid dosing events from time-stamped biometric data collected from wrist-worn devices.
Device
Lead sponsor
OpiAID
Industry
Eligibility
22 Years and older
Enrollment
420 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Wilmington, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 29, 2026, 4:13 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Vitamin D Status of Pregnant Women and Their Children in Eau Claire, South Carolina

NCT00412087
View directory record Official record
Conditions
Vitamin D Deficiency, Pregnancy
Interventions
cholecalciferol (vitamin D3), cholecalciferol
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
16 Years to 45 Years · Female only
Enrollment
564 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
1
States / cities
Columbia, South Carolina
Source: ClinicalTrials.gov public record
Updated Jul 29, 2016 · Synced Oct 29, 2026, 4:13 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Sofosbuvir Plus Velpatasvir With or Without Ribavirin in Treatment-experienced Subjects With Chronic HCV Infection

NCT01909804
View directory record Official record
Conditions
Hepatitis C
Interventions
SOF, VEL, RBV
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
323 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
40
States / cities
Long Beach, California • Los Angeles, California • Pasadena, California + 37 more
Source: ClinicalTrials.gov public record
Updated Nov 15, 2018 · Synced Oct 29, 2026, 4:13 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of Calderasib (MK-1084) With Midazolam and Digoxin in Healthy Participants (MK-1084-009)

NCT06575933
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
Calderasib, Midazolam, Digoxin
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Feb 11, 2026 · Synced Oct 29, 2026, 4:13 PM EDT
Terminated Not applicable Interventional

Mirror Therapy After Stroke: A Dosing Study

NCT02778087
View directory record Official record
Conditions
Stroke
Interventions
Mirror Box Therapy, Sham Mirror Box Therapy
Behavioral
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 99 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
West Haverstraw, New York
Source: ClinicalTrials.gov public record
Updated Feb 14, 2018 · Synced Oct 29, 2026, 4:13 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Cooperative Studies Program #563 - Prazosin and Combat Trauma PTSD

NCT00532493
View directory record Official record
Conditions
PTSD, Sleep Disorders
Interventions
prazosin, placebo
Drug · Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
304 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
15
States / cities
Loma Linda, California • Long Beach, California • Palo Alto, California + 12 more
Source: ClinicalTrials.gov public record
Updated May 1, 2018 · Synced Oct 29, 2026, 4:13 PM EDT
Completed Phase 2 Interventional Results available

Study to Investigate the Dose Response, Safety and Efficacy of Nebulized EP-101(SUN101) in Patients With Chronic Obstructive Pulmonary Disease (COPD): GOLDEN-1 Study

NCT01426009
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
EP-101 via nebulizer (eFlow®) 25 ug, EP-101 via nebulizer (eFlow®) 50 ug, EP-101 via nebulizer (eFlow®) 100 ug, Placebo EP-101, Tiotropium bromide via (Spiriva® Handihaler®), Ipratropium bromide Inhalation Solution via Handihaler® DPI, EP-101 via nebulizer (eFlow®) 200 ug
Drug
Lead sponsor
Sunovion Respiratory Development Inc.
Industry
Eligibility
40 Years to 75 Years
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
10
States / cities
Phoenix, Arizona • Los Angeles, California • DeLand, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated May 9, 2018 · Synced Oct 29, 2026, 4:13 PM EDT
Completed Phase 2 Interventional Results available

Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

NCT00873093
View directory record Official record
Conditions
B-cell Adult Acute Lymphoblastic Leukemia, B-cell Childhood Acute Lymphoblastic Leukemia, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Lymphoblastic Lymphoma, T-cell Adult Acute Lymphoblastic Leukemia, T-cell Childhood Acute Lymphoblastic Leukemia
Interventions
L-asparaginase, doxorubicin hydrochloride, therapeutic hydrocortisone, vincristine sulfate, cytarabine, prednisone, bortezomib, pegaspargase, methotrexate, etoposide phosphate, cyclophosphamide, filgrastim, leucovorin calcium, laboratory biomarker analysis, High Dose MTX
Drug · Biological · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
1 Year to 31 Years
Enrollment
148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
157
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 124 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2017 · Synced Oct 29, 2026, 4:13 PM EDT
Completed Phase 2 Interventional Results available

Probiotic Prophylaxis of Hirschprung's Disease Associated Enterocolitis (HAEC)

NCT00630838
View directory record Official record
Conditions
Hirschsprung Disease
Interventions
VSL#3, Placebo
Drug
Lead sponsor
University of Michigan
Other
Eligibility
1 Month to 12 Months
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
2
States / cities
Ann Arbor, Michigan • Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jul 19, 2016 · Synced Oct 29, 2026, 4:13 PM EDT
Recruiting Phase 1 Interventional

Neratinib and Fam-Trastuzumab Deruxtecan in Advanced Gastro-esophageal Cancer Patients

NCT05274048
View directory record Official record
Conditions
Gastric Cancer, Gastrointestinal Cancer, HER2 Gene Mutation
Interventions
Neratinib Pill, Fam-Trastuzumab Deruxtecan-Nxki (TDxD)
Drug
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
3
States / cities
Palo Alto, California • Buffalo, New York • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 29, 2026, 4:13 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Imaging the Effects of Stimulant Medication on Emotional Lability in Patients With ADHD

NCT01415440
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Lisdexamfetamine, Placebo
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
6 Years to 25 Years
Enrollment
117 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 2, 2022 · Synced Oct 29, 2026, 4:13 PM EDT
Completed Phase 2 Interventional Results available

Bosutinib in Adult Patients With Recurrent Glioblastoma

NCT01331291
View directory record Official record
Conditions
Glioblastoma
Interventions
bosutinib
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 25, 2016 · Synced Oct 29, 2026, 4:13 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir Fixed-Dose Combination With or Without Ribavirin in Participants With Chronic Genotype 1 HCV Infection Previously Treated With a Direct Acting Antiviral Regimen

NCT02536313
View directory record Official record
Conditions
Hepatitis C Virus Infection
Interventions
SOF/VEL/VOX, RBV
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Feb 25, 2019 · Synced Oct 29, 2026, 4:13 PM EDT